The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience
Abstract
BACKGROUND: There is a paucity of data on long-term management of type 1 autoimmune pancreatitis (AIP), a relapsing steroid-responsive disorder. OBJECTIVE: We describe our experience with treatment of relapses and maintenance of remission using steroid-sparing immunomodulators (IMs) and induction of remission using rituximab (RTX). METHODS: We obtained details of disease relapse and treatment in 116 type 1 AIP patients from clinic visits, medical records and telephone interviews. We compared relapse free survival in those treated with IMs versus those treated with steroids alone, assessed patients' response to RTX, and identified treatment-related complications. RESULTS: During a median follow-up of 47 months, 52/116 AIP patients experienced 76 relapse episodes. The first relapse was treated with another course of steroids in 24 patients, and with steroids plus IM in another 27 patients; subsequent relapse-free survival until a second relapse was similar in the two groups (p=0.23). 38 patients received an IM for >2 months; failure or intolerance of IM therapy occurred in 17 (45%). 12 patients with steroid or IM intolerance/resistance were treated with RTX, an antiCD20 antibody; 10 (83%) experienced complete remission and had no relapses while on maintenance therapy. Treatment-limiting side effects related to RTX were uncommon. CONCLUSIONS: In type 1 AIP relapses are common. Relapse-free survival is similar in those treated with steroids plus IM compared to those treated with steroids alone. Nearly half the patients on IMs will relapse during treatment. RTX is effective in the treatment of both IM resistant and steroid intolerant patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, J. H., Zen, Y., & Deshpande, V. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1104650 · Cited by 2,616
Shimosegawa, T., Chari, S. T., Frulloni, L., Kamisawa, T., Kawa, S., Mino-Kenudson, M., Kim, M.-H., Klöppel, G., Lerch, M. M., Löhr, M., et al. (2011) · Pancreas · doi:10.1097/mpa.0b013e3182142fd2 · Cited by 1,526
Self-citationDiagnosis of Autoimmune Pancreatitis: The Mayo Clinic Experience
Chari, S. T., Smyrk, T. C., Levy, M. J., Topazian, M. D., Takahashi, N., Zhang, L., Clain, J. E., Pearson, R. K., Petersen, B. T., Vege, S. S., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.05.017 · Cited by 972
Self-citationImmunoglobulin G4-associated cholangitis: clinical profile and response to therapy
Ghazale, A., Chari, S. T., Zhang, L., Smyrk, T. C., Takahashi, N., Levy, M. J., Topazian, M. D., Clain, J. E., Pearson, R. K., Petersen, B. T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.009 · Cited by 890
Self-citationStandard steroid treatment for autoimmune pancreatitis
Kamisawa, T., Shimosegawa, T., Okazaki, K., Nishino, T., Watanabe, H., Kanno, A., Okumura, F., Nishikawa, T., Kobayashi, K., Ichiya, T., et al. (2009) · Gut · doi:10.1136/gut.2008.172908 · Cited by 724
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details
Umehara, H., Okazaki, K., Masaki, Y., Kawano, M., Yamamoto, M., Saeki, T., Matsui, S., Sumida, T., Mimori, T., Tanaka, Y., et al. (2012) · Modern Rheumatology · doi:10.3109/s10165-011-0508-6 · Cited by 680
Zamboni, G., L�ttges, J., Capelli, P., Frulloni, L., Cavallini, G., Pederzoli, P., Leins, A., Longnecker, D., & Kl�ppel, G. (2004) · Virchows Archiv · doi:10.1007/s00428-004-1140-z · Cited by 663
Rituximab for the Treatment of IgG4-Related Disease: Lessons From 10 Consecutive Patients
Khosroshahi, A., Carruthers, M. N., Deshpande, V., Unizony, S., Bloch, D. B., & Stone, J. H. (2012) · Medicine · doi:10.1097/md.0b013e3182431ef6 · Cited by 489
Differences in Clinical Profile and Relapse Rate of Type 1 Versus Type 2 Autoimmune Pancreatitis
Sah, R. P., Chari, S. T., Pannala, R., Sugumar, A., Clain, J. E., Levy, M. J., Pearson, R. K., Smyrk, T. C., Petersen, B. T., Topazian, M. D., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.054 · Cited by 460
Self-citationTreatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
Ahmed, A. R., Spigelman, Z., Cavacini, L. A., & Posner, M. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062930 · Cited by 456
Cited by
Kamisawa, T., Zen, Y., Pillai, S., & Stone, J. H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60720-0 · Cited by 1,212
International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease
Khosroshahi, A., Wallace, Z. S., Crowe, J. L., Akamizu, T., Azumi, A., Carruthers, M. N., Chari, S. T., Della‐Torre, E., Frulloni, L., Goto, H., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39132 · Cited by 1,064
Self-citationPrimary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
Rituximab for IgG4-related disease: a prospective, open-label trial
Carruthers, M. N., Topazian, M. D., Khosroshahi, A., Witzig, T. E., Wallace, Z. S., Hart, P. A., Deshpande, V., Smyrk, T. C., Chari, S., & Stone, J. H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206605 · Cited by 726
Self-citationIgG4‐Related Disease: Clinical and Laboratory Features in One Hundred Twenty‐Five Patients
Wallace, Z. S., Deshpande, V., Mattoo, H., Mahajan, V. S., Kulikova, M., Pillai, S., & Stone, J. H. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39205 · Cited by 666
Metadata
- Authors
- Hart, P. A., Topazian, M. D., Witzig, T. E., Clain, J. E., Gleeson, F. C., Klebig, R. R., Levy, M. J., Pearson, R. K., Petersen, B. T., Smyrk, T. C., Sugumar, A., Takahashi, N., Vege, S. S., & Chari, S. T.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2012-08-30
- Volume
- 62
- Issue
- 11
- Pages
- 1607-1615
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2139500303
- Cited by
- 416
- References
- 19
- FWCI
- 20.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. https://app.cochat.ai/papers/10.1136/gutjnl-2012-302886
- The paper
- Hart, P. A., Topazian, M. D., Witzig, T. E., Clain, J. E., Gleeson, F. C., Klebig, R. R., Levy, M. J., Pearson, R. K., Petersen, B. T., Smyrk, T. C., Sugumar, A., Takahashi, N., Vege, S. S., & Chari, S. T. (2013). Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. https://doi.org/10.1136/gutjnl-2012-302886
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.